On September 18, 2024, CanSino Biologics held the 2024 semi-annual pharmaceutical and biopharmaceutical special performance briefing through web-based interactive text format at the Shanghai Stock Exchange listing roadshow center. The purpose of this briefing was to allow investors to have a more comprehensive understanding of the company's operational performance and financial condition in the first half of the year. The company released its semi-annual report on August 30 and addressed investors' concerns during the briefing. Attendees included Mr. Yu Xuefeng, Chairman and General Manager of the company, Mr. Cui Jin, Secretary of the Board of Directors, and Mr. Liu Ming, Acting Chief Financial Officer. Investors had the opportunity to submit questions to the designated company email address before 4 pm on September 17, the day before the briefing, to be answered during the event.

On September 18, 2024, CanSino Biologics held the 2024 semi-annual pharmaceutical and biopharmaceutical special performance briefing through web-based interactive text format at the Shanghai Stock Exchange listing roadshow center. The purpose of this briefing was to allow investors to have a more comprehensive understanding of the company's operational performance and financial condition in the first half of the year. The company released its semi-annual report on August 30 and addressed investors' concerns during the briefing. Attendees included Mr. Yu Xuefeng, Chairman and General Manager of the company, Mr. Cui Jin, Secretary of the Board of Directors, and Mr. Liu Ming, Acting Chief Financial Officer. Investors had the opportunity to submit questions to the designated company email address before 4 pm on September 17, the day before the briefing, to be answered during the event.